UNITED STATES
NUCLEAR REGULATORY COMMISSION
WASHINGTON, D.C. 20555

OFFICE OF THE
COMMISSIONER

July 30, 1979

MEMORANDUM FOR: Harold Denton, Director, NRR

FROM: John Ahearne

SUBJECT: USE OF THYROID BLOCKING AGENTS

Thank you for your memorandum of July 13 on this subject. As you pointed out "The NRC staff has been predisposed to require stockpiling of KI." You also noted that the Reg Guide 1.101 recommendation was qualified because the Food and Drug Administration had not developed guidance for the use of radioprotective drugs.

I understand the FDA has published a Federal Register Notice on the use of KI indicating that it is effective and the FDA does not have any problem with its use.

Your July 13 memorandum indicates that "The NRC staff will be meeting with FDA in the near future to expedite consideration of the matter." I would appreciate knowing what it is that must be expedited and when the meeting with FDA will be held. Also, I conclude from your memorandum that it had only been FDA in action that had prevented the NRC from requiring stockpiling of KI. Now that the FDA has acted, do we intend to impose such a requirement?

cc: Chairman Hendrie
Commissioner Gilinsky
Commissioner Kennedy
Commissioner Bradford
Secy
EDO

90009276

Rec'd Off. EDO
Date 8/1/79
Time 8:00 A.M.

8001080329